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Abstract
Background: Estimating the economic impact of influenza is complicated because the disease may have non-
specific symptoms, and many patients with influenza are registered with other diagnoses. Furthermore, in some
countries like Norway, employees can be on paid sick leave for a specified number of days without a doctor’s
certificate ("self-reported sick leave”) and these sick leaves are not registered. Both problems result in gaps in the
existing literature: costs associated with influenza-related illness and self-reported sick leave are rarely included. The
aim of this study was to improve estimates of total influenza-related health-care costs and productivity losses by
estimating these missing costs.
Methods: Using Norwegian data, the weekly numbers of influenza-attributable hospital admissions and certified
sick leaves registered with other diagnoses were estimated from influenza-like illness surveillance data using quasi-
Poisson regression. The number of self-reported sick leaves was estimated using a Monte-Carlo simulation model
of illness recovery curves based on the number of certified sick leaves. A probabilistic sensitivity analysis was
conducted on the economic outcomes.
Results: During the 1998/99 through 2005/06 influenza seasons, the models estimated an annual average of 2700
excess influenza-associated hospitalizations in Norway, of which 16% were registered as influenza, 51% as
pneumonia and 33% were registered with other diagnoses. The direct cost of seasonal influenza totaled US$22
million annually, including costs of pharmaceuticals and outpatient services. The annual average number of
working days lost was predicted at 793 000, resulting in an estimated productivity loss of US$231 million. Self-
reported sick leave accounted for approximately one-third of the total indirect cost. During a pandemic, the total
cost could rise to over US$800 million.
Conclusions: Influenza places a considerable burden on patients and society with indirect costs greatly exceeding
direct costs. The cost of influenza-attributable complications and the cost of self-reported sick leave represent a
considerable part of the economic burden of influenza.
Background
Influenza is a contagious respiratory illness with a long
history of causing human morbidity and mortality.
Despite extensive surveillance of seasonal influenza, its
economic costs are hard to quantify for at least two rea-
sons. First, only a small proportion of influenza infec-
tions are confirmed virologically, and a considerable
proportion of cases registered as pneumonia or other
diseases actually have influenza as the underlying cause
[1]. There are many studies on the statistical methods
for estimating excess hospitalization and mortality of
influenza-attributable diseases [2-4], but few economic
studies have incorporated the cost of these diseases. Sec-
ond, in earlier studies that have estimated the indirect
costs of influenza, self-reported sick leave has largely
been ignored. To our knowledge, self-reported sick leave
has only been estimated in small samples or through
surveys [5,6], but not in the general population, and it
has not been evaluated in combination with data on
influenza-like illness or disease recovery curve.
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Knowledge of the total costs of seasonal influenza is
important because such data are crucial for studying the
cost-effectiveness of influenza interventions (vaccination,
isolation, etc.). In addition, the disease burden of seaso-
nal influenza may be used to estimate the treatment
capacities that society may need in case of a pandemic.
The aim of this study was to estimate the direct and
indirect costs of seasonal influenza in Norway using
Norwegian registry data on disease occurrence, use of
health care services and sick leave certification. In this
article, we introduce a novel method for estimating the
costs of influenza based on influenza-like illness (ILI)
data and sick leave register data. Using a variety of
mathematical models, we estimated direct costs asso-
ciated with non-specific diagnoses and all types of indir-
ect costs, including self-reported absenteeism. Our
results regarding seasonal influenza could form the basis
for exploring the cost of a potential influenza pandemic.
Methods
There are two types of costs of influenza: direct costs,
which include the pharmaceutical costs and the medical
service costs, and indirect costs, which stem from job
absenteeism (productivity losses). A person infected
with influenza will end up in one of the three outcomes:
(1) ill but not medically attended; (2) ill with outpatient
visit(s); and (3) ill with hospitalization (inpatients). Indi-
viduals in all three outcomes incur pharmaceutical and
indirect costs, while only outpatients and inpatients
incur medical service costs. Therefore, the three out-
comes lead to four economic consequences: pharmaceu-
tical cost for all three outcome groups, medical service
costs for outpatients, medical service costs for inpati-
ents, and indirect cost for all the three groups. For some
of the costs, we estimated the number of events (hospi-
talization, sick leave days) and multiplied them by the
relevant unit costs. For the others, we estimated them
from aggregate cost data as reported in registries. In the
end, we considered the uncertainty in data and per-
formed a probabilistic sensitivity analysis. Our study
used a prevalence rather than incidence approach to
estimate cost-of-illness in part because influenza is not a
chronic disease and in part because of data availability.
We assumed that each person could have at most one
influenza episode during a season. We considered only
symptomatic cases, since the asymptomatic cases do not
contribute to the use of resources in the public health
care system or to the job absenteeism.
Data Sources
Data on influenza-like illness rates (ILI rates) by week
during the 1998/99 through 2006/07 seasons were
obtained from the Norwegian Institute of Public Health
(NIPH). The ILI rate for a given week is the proportion
of the number of general practitioner (GP) consultations
in which an ILI diagnosis [7] is given out of the total
number of consultations. Surveillance of influenza activ-
ity in Norway is based on weekly reports from 201 sen-
tinels covering approximately 15% of all GP
consultations in the country, and takes place from week
40 in one calendar year through week 20 in the next
calendar year. No data are available on influenza epi-
sodes during the summer months. We therefore define
an influenza season (year) as week 40 in one year
through week 20 in the next year. Laboratory tests of
influenza virus are only conducted for a minority of sus-
pected influenza cases, but ILI rates have been proven
to be a reliable proxy for influenza activity [8].
The attack rate ra refers to the percentage of the
entire population with symptomatic influenza during an
influenza season. This number is difficult to estimate
since a large number of cases will receive only home
care. NIPH estimates that the attack rate is between 5%
and 15% in Norway (B. Iversen, personal communica-
tion, 16 June 2008).
We obtained from the Norwegian Patient Registry
(NPR) weekly data on acute hospital admissions during
the 1997/98 through 2005/06 seasons and data on average
length of stay. The data included the number of hospital
admissions in a given week with primary ICD-10 diag-
noses of influenza (J10-J11) pneumonia (I20-I25), ischemic
heart disease (J12-J18) and all-cause hospital admissions.
We obtained diagnosis-related-group (DRG) data from
NPR for all patients admitted to hospital with ICD codes
influenza and pneumonia in the 2005/06 season. The
DRG weights and the year-specific monetary value of a
DRG point were acquired from a government publication
[9]. We assumed that all patients have to consult their
general practitioners before they are hospitalized.
Data on the weekly number of short-term doctor-cer-
tified sick leaves with ICPC-2 diagnoses of influenza
(R80), other airway diseases and all-cause sick leaves for
the 2000/01 through 2006/07 seasons were obtained
from the Norwegian Labour and Welfare Service
(NAV). In the following, “other airway diseases” means
all R diagnoses except R80 in ICPC-2 and was consid-
ered as one category of disease. We merged week 52
and week 53, regarding them both as week 52 since
week 53 has only a few days.
For pharmaceuticals used in relation to influenza-asso-
ciated illness, the only data available are those on sales
of Tamiflu. We obtained the data from the NIPH’s pre-
scription database [10]. For outpatient costs, we
obtained from NAV aggregate monthly medical service
costs of outpatients (GP visits, emergency room services
and medical specialist visits) from October to May for
the season 2005/06 with ICPC-2 code R80 (influenza)
and with ICPC-2 code R81 (pneumonia).
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All costs were measured in 2005/06 Norwegian kroner
(NOK) and converted to US dollars (US$) using the
exchange rate on 31 December 2005 (US$ 1 = NOK
6.75) [11]. Because we relied on aggregated registry data
with no patient-level information, there was no require-
ment for an ethics approval for such a study under Nor-
wegian regulations.
Pharmaceutical cost
We examined two types of pharmaceuticals: Tamiflu, a
medication that specifically targets at influenza, and other
symptom-relieving medications that can be used for either
influenza or cold symptoms. Tamiflu costs, including
VAT, were based on redemption of prescriptions from all
pharmacies in Norway. We used the average annual Tami-
flu sales minus 25% VAT in years 2004–2008 as a proxy
for the cost in 2005/06. To estimate the cost of other
symptom-relieving medications, we surveyed pharmacies
in Oslo, and found that their unit prices were approxi-
mately equal. Although a person with influenza may pur-
chase none or several of the symptom-relieving
medications, we initially assumed that an average of one
pack per person was purchased, and later varied this
assumption in the sensitivity analysis. The cost of other
symptom-relieving medications was calculated as the pro-
duct of the attack rate, the total population, the number of
medications purchased per person (initially = 1) and the
average price of these medications excluding VAT. Total
pharmaceutical cost is the sum of the costs of Tamiflu and
of other symptom-relieving medications.
Cost of outpatient services
The aggregated monthly costs for influenza diagnoses
were taken directly from NAV data for the 2005/06 sea-
son. To account for costs for pneumonia diagnoses with
influenza as an underlying cause ("influenza-related
pneumonia”), we multiplied NAV aggregate cost data
for pneumonia diagnoses by the proportion of patients
with influenza-related pneumonia. We assumed that this
proportion was the same as the corresponding propor-
tion calculated for pneumonia inpatients for the 2005/
2006 season (See below, Cost of inpatient services). We
further included the costs of influenza-related services
provided by private clinics, which have been estimated
to be approximately 20% of the costs in public sector
(T. Sundell, personal communication, 31 March 2009).
Cost of inpatient services
The medical service costs of inpatients were calculated
as the product of the number of influenza-related hospi-
talizations and the unit cost of hospitalization. While we
obtained the number of hospitalizations with influenza
as primary diagnosis directly from NPR data, we had to
estimate the numbers of hospitalizations of influenza-
related pneumonia and of influenza-related other dis-
eases, so-called excess hospitalization. We used three
quasi-Poisson regression models to examine whether
there is a correlation between the ILI rate and the num-
ber of hospitalizations for: 1) pneumonia, 2) ischemic
heart disease, and 3) all causes, respectively. In each
model, the dependent variable ˆ( , )Y w s was the pre-
dicted number of hospitalizations in week w of season s;
it was explained by three covariates: the reported ILI
rate, the week number w to capture weekly variations
and the season number s to capture yearly variations:
Y w s ILI w s w sILI w s
 , exp( ( , ) )( ) = + + +   0 (1)
The model was fitted using the glm-package in the
statistical software R version 2.7.1 (R Foundation for
Statistical Computing, Vienna, Austria). Poisson regres-
sion, often used to analyze count data, assumes a data
distribution in which the mean is equal to the variance.
In our case, the variance and the mean of the data were
not equal. Therefore we used quasi-Poisson regression
in which this condition can be relaxed. We tested the
model with the ILI rate of the same week and the ILI
rate of the preceding week separately. Since Norway has
five health regions (Eastern, Western, Southern, Middle
and Northern), we also repeated the regressions for each
of the regions separately.
The estimated number of excess hospitalizations of
pneumonia or other diseases was calculated by week as
the difference between the observed number of hospita-
lizations and the predicted number of hospitalizations
given minimal influenza activity. The latter was obtained
from Equation (1) by setting the influenza contribution
(ILI rate) to a baseline while leaving the other para-
meters and covariates as they were. We define the base-
line ILI rate as the mean of the lowest 10% of all ILI
rates in the study period to capture the small year-
round existing influenza activity.
The unit inpatient cost was calculated from Equation
(2). Variable j designated the ICD code influenza or
pneumonia when the patient is admitted into hospital
and variable i designated the DRG diagnosis at discharge
from the hospital. Let C j( ) be the average hospital cost
per patient admitted to hospital with ICD diagnosis j in
the 2005/06 season. It was calculated as a weighted sum:
C j
m i j
n j
w i UDRG
i
DRG DRG( )
,
* *=
( )
( ) ( )
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟∑ (2)
where n(j) is the total number of patients with ICD j,
mDRG(i,j) is the proportion of these patients with DRG
code i, wDRG(i) is the DRG points for diagnosis i and
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UDRG is the monetary value per DRG point in 2005/06
season (US$4612 or NOK31130 [9]). Hospitalizations
with unknown DRG codes were assigned 1 DRG point,
assuming that they represented an average patient.
Indirect costs
In Norway, doctors state a diagnosis on sick leave certifi-
cates while no information on diagnosis is available for
self-reported sick leave. Data from NAV provided infor-
mation on the number of doctor-certified sick leaves with
influenza diagnosis, and sick leaves with “other airway dis-
eases” diagnosis. We assumed that a fraction of the latter
had influenza as the underlying cause. This fraction was
estimated by means of quasi-Poisson regression in the
same way as excess hospitalization (see Step 1 below). In
addition to these doctor-certified sick leaves, employees
may take sick leave for up to three days (eight days with
some employers, see below) without a doctor’s certificate,
and this is denoted self-reported sick leave. If the person is
still sick on the fourth (ninth) day, a sickness certificate
from a doctor is needed in order to receive full salary.
Assuming that there is a constant recovery rate that fol-
lows a negative exponential function of time from the
onset of influenza (Figure 1), we estimated the total num-
ber and length of sick leaves on the basis of the number of
doctor-certified sick leaves (Step 2). The indirect costs of
self-reported and doctor-certified sick leave were then esti-
mated from the total number of sick leave days and the
average wage rate in Norway (Step 3).
Step 1: To estimate the number of non-influenza sick
leaves which had influenza as underlying cause, we set up
two quasi-Poisson regression models, same as Equation
(1), to explore the relationship between the ILI rates and
the number of sick leaves due to 1) “other airway diseases”
and 2) all causes, separately. We calculated excess sick
leave only when influenza was a statistically significant
predictor in the regression model.
Step 2: In Norway, about 50% of the working popula-
tion has an employer with “Agreement on Inclusive
Working Conditions” (Inkluderende Arbeidsliv or IA a
collective agreement between employer and employee).
Employees with IA employers have the right to stay at
home for up to eight calendar days with full salary with-
out a doctor’s certificate. About 40% of the working
population is employed with non-IA employers and can
stay at home for three calendar days with full salary
without a doctor’s certificate. The remaining 10% of the
work-active segment is self-employed, and this group is
not compensated financially during illness.
We assumed that if people with severe symptoms
choose to go to work, their productivity is negligible
and can be ignored.
The model was based on simulating the recovery curve
for influenza and “other airway diseases”. In this section,
index i refers to influenza and index a refers to “other air-
way diseases”. We assumed that recovery from illness
occurs with a constant rate g implying that the proportion
p(j) of people who are still ill at the end of day j after the
onset of symptoms is exponentially distributed p(j) = exp
(-jg). The mean recovery periods for influenza and “other
airway diseases” were assumed to be 1/gi = 5 days [12] and
1/ga = 7 days, respectively. The recovery period for “other
airway diseases” was 2 days longer than that of influenza
because the infections in this case were complications to
the primary influenza infection. Thus, we assumed that
recovery starts at the end of the second day counted from
the onset of symptoms; see Figure 1.
Based on the recovery curves we estimated the pro-
portions of people who need doctor-certified sick leave
for influenza (Figure 1): for non-IA employed pi(3) =
0.55 and for IA-employed pi(8) = 0.20. The correspond-
ing fractions for other airway disease are pa(3) = 0.87
and pa(8) = 0.42.
The densities of the working population with non-IA
and IA agreement are rnIA = 0.4 and rIA = 0.5, respec-
tively. The term Ni(s) refers to the total number of peo-
ple with certified sick leave due to influenza in season s,
and the values are obtained directly from the data. We
use Ni(s) to estimate the total number of people who
were on influenza sick leave (including both doctor-cer-
tified and self-reported) in season s, yi(s):
y s p y s p N
y s
N s
p
i nIA i i IA i i
i
i
nIA i
( ) ( ) ( ) ( )
( )
( )
( ( )
 
 
3 8
3
+ =
⇔ =
+
(s)
IA ip ( ))8
(3)
In the same way, we can estimate ya(s) from Na(s)
where ya(s) is the total number of people who take sick
Figure 1 Recovery curves for influenza and “other airway
diseases”.
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leave for “other airway diseases” associated with influ-
enza and Na(s) is the number of people who took doc-
tor-certified sick leave of “other airway diseases”
associated with influenza, which was obtained from the
quasi-Poisson regression.
Step 3: We calculated the number of sick leave days
from the number of sick leave people. The proportion
of people with influenza who recover on day j is given
by ri(j) = exp(-(j-1)gi)-exp(-jgi) for j≥1; these people will
be away from work for j days. For people who recovered
without visiting their doctors, we summed up the pro-
ducts of ri(j) and j days over the allowed 3 and 8 days
(the first two terms in the parentheses in Equation (4)),
and we assumed that the self-employed all recover
within a maximum of 8 days (the third term in the par-
entheses in Equation (4)). The working days lost for
people with certification is the sum of the average dura-
tion of sick leave with influenza di and the average days
prior to obtaining certification a (the 4th and the 5th
term in the parentheses in Equation (4)). We have no
information about when the certified sick leave is
initiated within the approved time frame. Therefore, we
simply set the onset of certified sick leave to be in the
middle of the periods, and factors of anIA = 2 and aIA =
4 days are added to the duration of sick leave di. Finally,
we multiply the expression by 5/7 since sick leave is
counted as calendar days, including weekends, while
there is no productivity loss from staying at home dur-
ing the weekends. In conclusion, we get the total num-
ber of working days lost due to influenza,Di(s):
D s
y s
jr j jr j
jr j
i
i
nIA i
j
IA i
j
se i
j
( )
( )
( ) ( )
( )
(= ∗ +
= =
=
∑ ∑5 7
1
3
1
8
1
 
+
8
3
8
∑ + +
+ +
( ) ( )
( ) ( ))
d p
d p
i nIA nIA i
i IA nIA i
 
 
(4)
Similarly, for “other airway diseases”, the loss of work-
ing days is:
D s
y s
r j r j
j r j
a
a
nIA a IA a
j
se a
( )
( )
( ) ( ) ( )
( ) ( )
(= 5
7
3 1 2
2
1
6
∗ + +
+ +
=
∑ 

j
a nIA nIA a
a IA nIA a
d p
d p
=
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1
6
3
8
( ) ( )
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 
 
(5)
The total number of working days lost related to
influenza in season s is D(s) = Di(s)+Da(s). We multi-
plied D(s) by the mean daily wage for the 2005/06 sea-
son. An extra 40% was added to account for the value
of productivity produced by workers but not returned to
them as wage. This includes employer tax, payment for
holiday and pension contributions in Norway [13-15].
To estimate the productivity loss from parents taking
care of sick children, we assumed that each sick child
requires two days of attendance at home from one par-
ent [16]. The number of sick children was the product
of the attack rate (mean 7.5%, range: 5%–10%) and the
population under 10 years old. The value of one day’s
work was the same as that in the previous paragraph.
We multiplied the number of parents affected, the num-
ber of days (assumed to be 2) and the value of one day’s
productivity and used the result as an estimation of the
productivity loss from taking care of sick children.
Sensitivity analysis
We explored the uncertainty of the data through prob-
abilistic sensitivity analyses using Monte Carlo simula-
tion. We varied the attack rate, the number of packs
purchased in pharmacies per person, the outpatient
cost, the percentage of outpatient cost in the private
clinics, DRG points for hospitalizations and the number
of hospitalizations (see above and Table 1 for details).
We expressed the uncertainty in terms of 95% confi-
dence interval for each of the cost components.
We summed the pharmaceutical cost (P), the outpati-
ent cost (O) and the inpatient cost (I) to obtain the total
direct cost, assuming independence between the three
sub-costs. We calculated the variation of the total direct
cost (T) as ΔT:
ΔT
T T
P P O O I I
up low
up low up low up low
= −
− + − + −
( )
( ) ( ) ( )= 2 2 2
(6)
where indices up and low refer to the 95% upper and
lower confidence interval. The upper and lower bounds
of the total direct cost were then calculated as Tup/low =
T ± 0.5*ΔT.
In the indirect cost part, we varied three variables: the
recovery period, the number of days before obtaining
doctor’s certificate and the distribution of people in IA,
non-IA companies and the self-employed (Table 1).
Results
Pharmaceutical costs
With an attack rate of 7.5%, a population of 4.64 million
(2005/06) and an average of one pack purchased per
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person in pharmacies, the pharmaceutical cost excluding
Tamiflu was $2.58 million per year. During the 2004
through 2008 years, the average cost of Tamiflu was
$285 600 (Table 2).
Costs of outpatient services
In the 2005/06 season, the cost of influenza outpatient
services was $2.8 million. The average annual ILI rate in
that season was 83% of the average annual ILI rate in
the period 1998/99 through 2006/07 seasons. We
assumed that the cost of that season also represented
83% of the cost of a season with an average annual ILI
rate. Therefore the estimated cost of influenza outpati-
ent service would be $3.37 million given an average
annual ILI rate. In addition, 1 in 14 pneumonia hospita-
lizations was influenza-related, resulting in an influenza-
related pneumonia cost of $44 000 ($53 000 with aver-
age annual ILI rate). The cost of private clinic services
was estimated to be $683 000, contributing to a total
outpatient cost of $4 million (Table 2).
Costs of inpatient services
In the quasi-Poisson regression models, Equation (1),
the ILI rate was found to be a significant predictor of
acute all-cause hospitalizations (Ptotal < 0.001) and pneu-
monia hospitalizations (Ppneu < 0.001) at the national
level. For ischemic heart disease, however, the
association was not significant at the 5% significance
level (Pisch = 0.06). Similar patterns were present at
regional level, although in the Middle and Northern
health regions, ILI rate was a significant predictor of
hospital admission for ischemic heart disease (Pisch <
0.05). The weekly ILI rates and hospitalizations were
plotted in Figure 2.
During the 1998/99 through 2005/06 seasons, the
model estimated an average of 2700 influenza-related
hospitalizations per year, among which 450 were regis-
tered as influenza, while 1400 were registered as pneu-
monia but having influenza as the underlying cause.
The remaining 890 influenza-related hospitalizations
had various other diagnoses that could not be identified
(Table 3).
The number of influenza-attributable hospitalizations
varied from year to year with a threefold number of
hospitalizations in the most severe year (1998/99) com-
pared to the mildest year (2000/01) (Table 3). There
was an annual average of 40 (SE = 7) influenza and
excess pneumonia hospitalizations per 100 000 popula-
tion during the study period (Table 3).
Among the patients admitted to hospital in the 2005/
06 season, the cost for patients diagnosed with influenza
represented a weighted average of 0.59 DRG points
($2721) while patients with pneumonia represented a
weighted average of 1.47 points ($6780).
Table 1 Factors for estimating direct costs of seasonal influenza in the 2005/06 season
Direct cost Mean Distribution Parameters
Pharmaceutical cost Attack rate (%) 7.50 Beta b a = 31.91 b = 393.5
Cost per pack (USD) 7.4
Number of packs 1.00 Gamma c k = 6.83 Θ = 0.15
Population (2005/06) 4 640 219
Outpatient costa Adjusted influenza+pneumonia cost 3 415 900 Gamma c k = 25.00 Θ = 13.66e3
Percentage in private clinics 20.00 Beta b a = 12.60 b = 50.40
Inpatient cost Number of influenza hospitalization 446 Gamma c k = 43.02 Θ = 10.37
Number of pneumonia hospitalization 1 382 Gamma c k = 35.48 Θ = 38.95
Number of other hospitalization 890 Gamma c k = 148.6 Θ = 5.99
DRG points for influenza hospitalization 0.59 Gamma c k = 25.00 Θ = 0.02
DRG points for pneumonia hospitalization 1.47 Gamma c k = 25.00 Θ = 0.06
DRG points for other hospitalization 1.00 Gamma c k = 25.00 Θ = 0.04
Indirect cost
Sick leave Recovery period for influenza (days) 5.00 Normal s = 0.50
Recovery period for other airway disease (days) 7.00 Normal s = 0.50
Percentage with IA employers 50.0 Normal s = 1.67
Percentage with non-IA employers 40.0 Normal s = 2.36
Percentage self-employed 10.0 Normal s = 1.67
Days prior to sick leave for non-IA employees 2.50 Uniform range [2.00: 3.00]
Days prior to sick leave for IA employees 4.00 Normal s = 0.50
a Outpatient cost includes costs from GP visits, emergency room services and medical specialist visits.
b f x
B
x x( ; , )
( , )
( )   
 
= −
− −1 11 1 , where B is the Beta function.
c f x k x e
k
k x
k; , ( )
/ 
( ) = − −1
Γ , where Γ is the Gamma function.
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The total inpatient cost was on average $15 million
per year during the 1998/99 through 2005/06 seasons
while the total direct economic cost of influenza was
$22 million (Table 2).
Indirect cost
In the quasi-Poisson regression model, the ILI rate was
found to be a significant predictor of sick leave for
“other airway diseases”. The ILI rate of the same week
was a stronger predictor than that of the preceding
week (Pother-air-sick < 0.001). We did not find a significant
association between the ILI rate and all-cause sick leave,
either for the same week (Ptot-sick = 0.21) or for the pre-
ceding one (Ptot-sick-1 wk = 0.11). The weekly ILI rates
and sick leaves were plotted in Figure 3.
On average there were 48 300 people certified sick
with an influenza diagnosis each year and 11 000 people
certified sick with influenza-associated “other airway dis-
eases” (Table 4).
According to aggregate data from NAV, the average
mean duration of doctor-certified sick leave was 7.2
days (range: 6.9 to 7.5) for influenza and 10.6 days
(range: 10.1 to 10.9) for “other airway diseases” in the
period 2000/01 through 2005/06.
The model results predicted that each year on average
104 700 people self-reported sick leave for influenza
while 8 700 self-reported sick leave for “other airway
diseases” attributable to influenza (Table 5). For influ-
enza, the number of self-reported sick leaves repre-
sented 68% of the total sick leaves and 39% of the
working days lost. For “other airway diseases” that is
influenza-related, the corresponding numbers were 44%
of the sick leaves and 22% of the working days lost.
During the 2000/01 through 2006/07 seasons, there
were on average 172 600 sick leaves due to influenza
per year, including 153 000 sick leaves for influenza and
19 600 sick leaves for “other airway diseases” attributa-
ble to influenza (Table 5). The total number of people
who were absent from work represented approximately
8% of the total workforce (approximate 2 million). In
total, 793 000 working days were lost due to influenza,
representing a total productivity loss of $231 million.
Parents taking care of sick children represented an
estimated number of 98 800 working days lost, or a pro-
ductivity loss of $29 million, approximately 13% of total
productivity loss.
The total cost of influenza was $253 million per year,
ranging from $220 to $299 million depending on sever-
ity (Table 2).
Sensitivity analysis
In the Monte Carlo simulation, the total pharmaceutical
costs varied from $0.98 million to $6.69 million due to
the uncertainty in attack rate and the number of symp-
tom-reducing medications purchased per person. Outpa-
tient costs varied from $2.5 million to $6.2 million while
inpatient costs ranged from $7 million to $27 million
(Table 2).
Mean direct costs were $22 million with 95% confi-
dence intervals of ($11 million, $32 million), and mean
indirect costs were $231 million (95% C.I., $200 million,
$268 million) (Table 2).
Discussion
Our results indicate that seasonal influenza in Norway
costs approximately $250 million per year, of which the
Table 2 Average costs of seasonal influenza (2005US$)
Mean Lower bound Upper bound
(95% CI) (95% CI)
Pharmaceutical cost Tamiflu 285 665
Other 2 575 322 691 010 6 401 872
Sub-total 2 860 986 976 675 6 687 536
Outpatient cost Public 3 415 900 2 215 418 4 758 469
Private 683 180 243 696 1 475 125
Sub-total 4 099 080 2 459 114 6 233 594
Inpatient cost Influenza 1 213 563 584 232 2 295 357
Pneumonia 9 369 162 4 126 879 17 933 785
Other 4 104 548 2 248 653 6 932 703
Sub-total 14 687 272 6 959 764 27 161 845
Direct cost 21 647 339 10 982 153 32 312 524
Indirect cost Employees’ own sickness 202 247 136 180 927 219 229 780 678
Employees’ children’s sickness 28 763 862 28 763 862 28 763 862
Sub-total 231 010 998 200 103 205 268 132 650
Total 252 658 337 220 086 635 298 627 517
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Figure 2 Weekly influenza-like illness consultation per 100 consultations and influenza-related hospitalizations (The negative
differences are set to zero in the figure but subtracted in calculation.)
Table 3 Predicted numbers of influenza-related hospitalizations during the 1998/99 through 2005/06 seasons
Hospitalization P&Ia hospitalization Dominant
Influenza Pneumonia Others Total per 105 persons strainb
1998/99 615 2312 1071 3998 66 H3N2
1999/00 717 2207 986 3910 65 H3N2
2000/01 229 552 531 1312 17 H1N1
2001/02 344 1087 1081 2512 32 H3N2
2002/03 210 659 675 1545 19 None
2003/04 651 1619 834 3104 50 H3N2
2004/05 417 1539 1097 3053 42 H3N2
2005/06 387 1080 845 2311 32 B
Mean 446 1382 890 2718 40
SE 68 232 73 351 7
a Pneumonia and influenza
b Data from Norwegian Institute of Public Health
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indirect costs represent approximately 90%. Using national
databases, we employed novel methods to estimate the
economic cost of seasonal influenza. First, we modeled
total excess hospitalizations attributable to influenza in
order to estimate hospitalizations that did not list influ-
enza as the diagnosis. Second, we developed a model to
predict the cost of self-reported sick leave by combining
data on GP-certified sick leave with disease recovery
curves. Absence from work without GP certification is dif-
ficult to estimate and, to our knowledge, has only been
estimated based on small samples and surveys in earlier
studies [5,6]. The novel method presented here is general
and may be adapted to estimate self-reported sick leave
for other infectious diseases and in other countries.
Our results on influenza-related sick leave suggest that
the number of people who took self-reported sick leave
accounted for approximately 65% of the total number of
people who took sick leave and that the number of days
of self-reported sick leave accounted for 36% of the total
number of sick leave days. Parental sick leave represents
Figure 3 Weekly influenza-like illness consultation per 100 consultations and influenza-related sick leave (The negative differences are
set to zero in the figure but subtracted in calculation.)
Table 4 Number of people with doctor-certified sick
leave according to diagnosis
Season Influenza Other airway diseases
2000/01 60 768 7 187
2001/02 57 453 11 457
2002/03 34 694 6 867
2003/04 45 935 15 296
2004/05 44 694 12 095
2005/06 37 084 9 092
2006/07 57 340 14 758
Mean 48 281 10 964
SE 3 935 1 284
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approximately one-tenth of the total indirect cost. The
average duration of doctor-certified sick leave days was
7.2 days (range: 6.9 to 7.5) during the 2000/01 through
2005/06 seasons, which is slightly longer than the find-
ings in studies in other European countries [6]. In Nor-
way, employees receive full salary during sick leave, and
this may explain longer spells of absenteeism in Norway.
According to our analyses, only 1 in 6 influenza-attri-
butable hospitalizations had influenza as the diagnosis. 1
in 14 pneumonia hospitalizations had influenza as under-
lying cause and these hospitalizations accounted for
approximately half of the influenza-attributable hospitali-
zations. We expected some of ischemic heart disease hos-
pitalizations might also be caused by influenza. However,
the national level results did not support this at a 5% sig-
nificance level. In the Northern and Middle regions, how-
ever, there was a significant correlation between
hospitalizations for cardiovascular disease and ILI rates,
but we do not have a clear explanation for this difference.
We validated our method by comparing our results to
the results produced by the software program StatFlu
[17]. StatFlu was developed by the Swedish Board of
Health and Welfare to estimate hospital load in the
event of pandemic influenza. Using Norwegian demo-
graphic data, the StatFlu program estimated 1900
annual hospitalizations with an attack rate of 5%, and
twice as many with an attack rate of 10%. Our results of
approximately 2700 annual hospitalization per year were
consistent with an attack rate between 5% and 10%.
This suggests that that our assumption of an attack rate
of 7.5% for seasonal influenza in Norway may be reason-
able. Our finding that approximately 8% of the working
population took influenza-related sick leave also sup-
ports this assumption.
We did not include the cost of lost lives in the eco-
nomic analyses. The majority of seasonal influenza fatal-
ities occurred to people over 65 years of age [18], and
consequently the value of permanently lost productivity
is minor. However, other studies have found that lost
lives represent a considerable economic burden of influ-
enza [19,20], and therefore our study may provide a
conservative estimate of the economic burden of seaso-
nal influenza.
Historic data on pandemics in the 20th century indi-
cate that attack rates range from approximately 15% to
30% [21], representing a 2-fold to 4-fold increase in the
attack rates compared to the 7.5% we assumed for sea-
sonal influenza in this study. The results of the study
may be used to shed some lights on the cost of an influ-
enza pandemic. For example, assuming a pandemic
attack rate of 3 times the seasonal average, we simply
scale up the seasonal influenza cost by a factor of 3. In
addition, there is a cost for the Norwegian government
of stockpiling Tamiflu for pandemic influenza (K. Sæle-
nsminde, personal communication, 10 November 2009).
The estimated total cost for pandemic influenza is
approximately $800 million. With attack rates of 2 and
5 times the seasonal average, the estimated costs are
$550 million and $1300 million, respectively. On the
other hand, the Norwegian government has spent NOK
600 million ($88 million) on pandemic influenza vaccine
(K. Sælensminde, personal communication, 10 Novem-
ber 2009), and with administrative costs included, this
amounts to approximately $100 million. Hence, if the
vaccine can prevent approximately 12% of the influenza
cases in a susceptible population, it will be cost-effective
or even cost saving unless there are severe side effects.
This pandemic cost calculation is highly simplistic,
neglecting changes in the age-specific attack rates, sever-
ity of influenza-related diseases and potential costs from
disruption of commerce and societal functions. In addi-
tion, the permanent productivity losses from mortality
of young people may be considerable. Therefore, the
pandemic influenza costs that we present above are
Table 5 Sick leave according to type and diagnosis
Number of people (95% CI) Number of days (95% CI)
Mean L-bound U-bound Mean L-bound U-bound
Influenza Doctor-certified 48 281 343 839 327 159 360 272
Self-reported 104 673 79 664 142 486 219 885 172 195 288 302
Both types 152 954 127 945 190 767 563 724 513 486 632 653
Other airway disease Doctor-certified 10 964 102 346 98 390 106 254
Self-reported 8 717 7 234 10 476 28 460 23 572 34 254
Both types 19 681 18 198 21 440 130 806 124 227 137 867
Both Doctor-certified 59 245 446 185 425 549 466 526
Self-reported 113 390 86 898 152 962 248 345 195 767 322 556
Both types 172 635 146 143 212 207 694 530 621 316 789 082
Having sick children 49 389 32 926 65 852 98 777 65 852 131 703
Total 222 024 179 069 278 059 793 307 687 168 920 785
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clearly underestimated. However, the novelty of the
virus coupled with changes over time in social structure
and progress in medical technology made it difficult to
determine the impact from historic data.
This study has several limitations. First, there are no
registry data available for over-the-counter drugs for
influenza. Second, the ILI reports from GPs, the hospital
diagnoses and the sick leave diagnoses cannot be vali-
dated, and some might be inaccurate. Third, the num-
bers of excess hospitalizations depend on how the ILI
baseline rate without influenza outbreaks is defined.
Here, there is no agreement on the best research
practice.
Conclusion
Accurate estimates of the economic burden of influenza
are essential for designing appropriate policies in public
health. Standard measures of the societal costs of influ-
enza generally omit the costs of influenza-related disease
for which influenza is not the diagnosis and of self-
reported sick leave. Our results indicate that including
health care costs of influenza-related diseases may
increase total costs by approximately 30% and that
including the costs of self-reported sick leave may
increase total costs by 40%. Based on these findings,
vaccination for pandemic influenza may be cost-effective
even at low prevention rates.
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